Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Biogen: Amevive decision eases Avonex woes

Biogen's Amevive has moved a step closer to the market, as an FDA panel urged its approval for treating adult chronic psoriasis. If the drug is approved, it will be a welcome diversification for Biogen. Its only marketed product, MS drug Avonex, is under serious threat from the FDA's recent decision to approve Serono's Rebif in the US.

Published By Datamonitor
29 May 2002
CommentWire
CommentWire

Roche: making Pegasys fly in Europe

Roche can now market Pegaysys to EU hepatitis C sufferers. It should win market share from Schering-Plough's Peg Intron, which hit EU markets last year. But hepatitis C is increasingly being treated with combined pegylated interferon and ribavirin - so until Roche gains approval for its ribavirin variant, Copegus, Roche will not be able to fully displace Schering's patient capture.

Published By Datamonitor
25 Jun 2002
CommentWire
CommentWire

Roche: T-20 demand will outstrip supply

Roche's new HIV drug, T-20, should launch next year. However, it already seems that producing sufficient quantities of T-20 will be a challenge - particularly before the full-scale production facility for the drug comes online. Roche will need to manage customer expectations carefully in the early stages of T-20's launch, or risk losing confidence.

Published By Datamonitor
06 Aug 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002
CommentWire
CommentWire

Chugai/Roche: the best of both worlds

Chugai and Roche's merger has come at an important time for the Japanese pharmaceutical industry. As regulatory changes make it easier for western drugs and drug-makers to enter, Japanese pharma companies are facing fewer opportunities to benefit from in-licensing. As a result, innovation is becoming vitally important for domestic growth.

Published By Datamonitor
03 Oct 2002
CommentWire
CommentWire

Novartis: Prexige proves a pain for Pharmacia

New trial results suggest that Novartis' 400mg Prexige is superior to 200mg Celebrex at providing pain relief for osteoarthritis patients. However, further studies will be needed to consider like-for-like tests and cardiovascular side effects. The results of these will be critical to Prexige's positioning in the extremely competitive pain relief market.

Published By Datamonitor
04 Oct 2002
CommentWire
CommentWire

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor
18 Nov 2002
CommentWire
CommentWire

Novartis: star potential for Starlix in diabetes prevention

The study determined an effective, safe dose for Novartis' type 2 diabetes drug Starlix in patients suffering from IGT, a pre-diabetic condition. This information will be used in further studies, which could lead to Starlix's approval in the potentially huge diabetes prevention market. However, this is unlikely to happen before 2008.

Published By Datamonitor
27 Nov 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.